Research Use Only · User Discretion Advised

CJC-1295 with DAC

$66.00

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog engineered with an extended half-life reaching approximately 7 days in research models, enabling less frequent administration. The DAC modification binds to serum albumin, protecting the peptide from degradation.

Research demonstrates that CJC-1295 DAC produces sustained elevation of GH and IGF-1 levels in both preclinical models and clinical research settings. This extended-release characteristic appeals to researchers seeking continuous axis stimulation without frequent dosing.

Scientific literature documents the compound across multiple research protocols examining long-term GH effects on body composition, recovery markers, and metabolic parameters. Comparisons with the NO DAC variant show different kinetic profiles suited to distinct research objectives.